Acurx Pharmaceuticals, Inc. (ACXP) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Staten Island, NY, アメリカ. 現CEOは David Luci.
ACXP を有する IPO日 2021-06-25, 4 名の正社員, に上場 NASDAQ Capital Marke, 時価総額 $4.41M.
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
